<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="T0003" orientation="landscape" position="float">
 <label>Table 3</label>
 <caption>
  <p>Regimens for treating DR-TB and HIV components in patients with established coinfection</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th rowspan="1" colspan="1">Regimens for DR-TB component</th>
    <th rowspan="1" colspan="1">Regimens for HIV component</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td rowspan="1" colspan="1">
     <bold>Isoniazid (H) mono/polydrug resistance</bold>
     <break/>
     <bold>WHO 2016</bold>
     <list list-type="bullet">
      <list-item>
       <p>IP (3–6 months): Lfx + Km + R + E + Z</p>
      </list-item>
     </list>
     <break/>CP (6 months): Lfx + R + E + Z
     <break/>
     <bold>WHO 2019</bold>
     <list list-type="bullet">
      <list-item>
       <p>All oral regimen (6 months): Lfx + R + E + Z (No IP or CP)</p>
      </list-item>
      <list-item>
       <p>If Lfx cannot be used (9 months): high-dose Mfx + R + E + Z</p>
      </list-item>
      <list-item>
       <p>If high-dose Mfx or Z cannot be used, replace with Lzd; if not Lzd, replace with Cfz; if not Lzd + Cfz, add Cs</p>
      </list-item>
      <list-item>
       <p>Neither high-dose Mfx nor Z can be used (9 months): add two of three in order of preference — Lzd, Cfz, Cs</p>
      </list-item>
     </list>
     <break/>
     <bold>MDR-TB/RR-TB (longer or conventional)</bold>
     <break/>
     <bold>WHO 2016</bold>
     <list list-type="bullet">
      <list-item>
       <p>IP (6–9 months): Lfx + Km + Eto or Pto + Cs or Tzd + Z + E</p>
      </list-item>
     </list>
     <break/>CP (18 months): Lfx + Eto or Pto + Cs or Tzd + E
     <break/>
     <bold>(Also used in trials: STREAM and TB PRACTECAL trials — regimen A; End TB — regimen F)</bold>
     <list list-type="bullet">
      <list-item>
       <p>All-oral regimen (18–20 months; 6 months): Bdq+ Lfx + Lzd + Cfz + Cs (no IP or CP)</p>
      </list-item>
     </list>
     <break/>
     <bold>WHO 2019</bold>
     <list list-type="bullet">
      <list-item>
       <p>Abovementioned all-oral regimen preferred</p>
      </list-item>
     </list>
    </td>
    <td rowspan="1" colspan="1">
     <bold>First-line regimens (WHO-approved)</bold>
     <break/>
     <bold>Adults</bold>
     <break/>
     <bold>Two NRTIs + NNRTI or integrase inhibitor</bold>
     <list list-type="bullet">
      <list-item>
       <p>TDF + 3TC or FTC + Efv 600 mg/day in FDC (preferred combination)</p>
      </list-item>
     </list>
     <break/>Alternative combination if above drugs contraindicated or not available:
     <list list-type="bullet">
      <list-item>
       <p>Azt + 3TC or FTC + Efv 600 mg/day</p>
      </list-item>
      <list-item>
       <p>Azt + 3TC or FTC + Nvp</p>
      </list-item>
      <list-item>
       <p>TDF + 3TC or FTC + Nvp</p>
      </list-item>
      <list-item>
       <p>Abc + 3TC or FTC + Efv 600 mg/day</p>
      </list-item>
      <list-item>
       <p>Abc + 3TC or FTC + Nvp</p>
      </list-item>
      <list-item>
       <p>TDF + 3TC or FTC + Dtg or Ral</p>
      </list-item>
     </list>
     <break/>(better toxicity profile or less interaction with second-line drugs)
     <list list-type="bullet">
      <list-item>
       <p>TDF + 3TC or FTC + Efv 400 mg/day</p>
      </list-item>
      <list-item>
       <p>D4T should be avoided</p>
      </list-item>
     </list>
     <break/>
     <bold>Children 3–10 years of age</bold>
     <list list-type="bullet">
      <list-item>
       <p>Abc + 3TC + Efv (preferably) or Nvp</p>
      </list-item>
      <list-item>
       <p>Azt or TDF + 3TC or FTC + Efv (preferably) or Nvp</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">
     <bold>Modification in initial 6 months</bold>
     <list list-type="bullet">
      <list-item>
       <p>If Lfx cannot be used, replace with high-dose Mfx</p>
      </list-item>
      <list-item>
       <p>If high-dose Mfx cannot be used, replace with Dlm</p>
      </list-item>
      <list-item>
       <p>If high-dose Mfx and Dlm cannot be used, addition of two drugs from replacement sequence containing group C drugs in order Z, Am, Eto, PAS, E, Imp-Cln or Mpm, Amx-Clv</p>
      </list-item>
      <list-item>
       <p>If Bdq cannot be used, replace with Dlm</p>
      </list-item>
      <list-item>
       <p>If Dlm cannot be used, addition of two drugs from replacement sequence containing group C drugs</p>
      </list-item>
      <list-item>
       <p>If one of Lzd, Cfz, or Cs cannot be used, no replacement if Bdq and Lfx/high-dose Mfx can be given</p>
      </list-item>
      <list-item>
       <p>If two or three of Lzd, Cfz, or Cs cannot be used, replace with two drugs from replacement sequence</p>
      </list-item>
      <list-item>
       <p>If three of five drugs from regimen cannot be used, replace with three drugs from replacement sequence</p>
      </list-item>
     </list>
     <break/>
     <bold>Modification after 6 months</bold>
     <list list-type="bullet">
      <list-item>
       <p>If no drug (Lfx, Lzd, Cfz, Cs) can be used, no replacement</p>
      </list-item>
      <list-item>
       <p>If two drugs cannot be used, replace with two drugs from replacement sequence</p>
      </list-item>
     </list>
    </td>
    <td rowspan="1" colspan="1">
     <break/>
     <bold>Children ≤3 years of age</bold>
     <list list-type="bullet">
      <list-item>
       <p>Abc or Azt + 3TC + LVP/r (preferred) or Nvp</p>
      </list-item>
      <list-item>
       <p>Abc + 3TC + Azt (preferred in case of HIV and TB coinfection)</p>
      </list-item>
     </list>
     <break/>
     <bold>Second-line regimens (WHO-approved)</bold>
     <break/>Indicated when first-line regimens ineffective or fail, as detected by CD4 count or virological load
     <break/>
     <bold>Adults</bold>
     <break/>
     <bold>Two NRTIs + boosted PI</bold>
     <list list-type="bullet">
      <list-item>
       <p>If first-line regimen contains TDF: (Azt or Abc) + 3TC + Lpv/r or Atv/r or Drv/r</p>
      </list-item>
      <list-item>
       <p>If first-line regimen contains Azt or d4T: TDF + 3TC or FTC + Lpv/r or Atv/r or Drv/r</p>
      </list-item>
     </list>
     <break/>
     <bold>Alternative regimen</bold>
     <list list-type="bullet">
      <list-item>
       <p>Dtg or Ral + Lpv/r</p>
      </list-item>
     </list>
     <break/>
     <bold>Children up to 10 years of age</bold>
     <list list-type="bullet">
      <list-item>
       <p>If first-line regimen contains Abc or TDF: Azt + 3TC or FTC</p>
      </list-item>
      <list-item>
       <p>If first-line regimen contains Azt or D4T: (Abc or TDF) + 3TC or FTC</p>
      </list-item>
      <list-item>
       <p>If first-line regimen contains Lpv/r: Ral</p>
      </list-item>
      <list-item>
       <p>If first-line regimen contains Efv or Nvp: Lpv/r or Atv/r</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">
     <bold>MDR-TB with additional FQ resistance (pre-XDR-TB)</bold>
     <list list-type="bullet">
      <list-item>
       <p>IP (6–9 months): Mfx + Km + Eto or Pto + Cs or Tzd + Z + Lzd + Cfz</p>
      </list-item>
     </list>
     <break/>CP (18 months): Mfx + Eto or Pto + Cs or Tzd + Lzd + Cfz
     <break/>Regimen containing newer drug Bdq 
     <list list-type="bullet">
      <list-item>
       <p>IP (6–9 months): Km + Eto or Pto + Cs or Tzd + Z + Lzd + Cfz + (6 months) Bdq</p>
      </list-item>
     </list>
     <break/>CP: (18 months): Eto or Pto + Cs or Tzd + Lzd + Cfz
     <break/>
     <bold>MDR-TB with additional SLID resistance (pre-XDR-TB)</bold>
     <list list-type="bullet">
      <list-item>
       <p>IP (6–9 months): Lfx + Cm + Eto or Pto + Cs or Tzd + Z + Lzd + Cfz</p>
      </list-item>
     </list>
     <break/>CP (18 months): Lfx + Eto or Pto + Cs or Tzd + Lzd
     <break/>Regimen containing newer drug Bdq 
     <list list-type="bullet">
      <list-item>
       <p>IP (6–9 months): Lfx + Cm + Eto or Pto + Cs or Tzd + Z + Lzd + Cfz + (6 months) Bdq</p>
      </list-item>
     </list>
     <break/>CP (18 months): Lfx + Eto or Pto + Cs or Tzd + Lzd
     <break/>
     <bold>XDR-TB</bold>
     <list list-type="bullet">
      <list-item>
       <p>IP (6–9 months): Mfx + Cm + Eto or Pto + Cs or Tzd + Z + Lzd + Cfz + E</p>
      </list-item>
     </list>
     <break/>CP (18 months): Mfx + Eto or Pto + Cs or Tzd + Lzd + Cfz + E
     <break/>Regimen containing newer drug Bdq 
     <list list-type="bullet">
      <list-item>
       <p>IP (6–9 months): Cm + Eto or Pto + Cs or Tzd + Z + Lzd + Cfz + E + 6 months Bdq</p>
      </list-item>
     </list>
     <break/>CP (18 months): Eto or Pto + Cs or Tzd + Lzd + E
    </td>
    <td rowspan="1" colspan="1">
     <bold>Important considerations for using ART</bold>
     <list list-type="bullet">
      <list-item>
       <p>Efv preferred over Nvp, as potential hepatotoxicity of Nvp with anti-TB therapy</p>
      </list-item>
      <list-item>
       <p>If patient already on Nvp-based ART, then switch to Efv once anti-TB medication started and to be continued</p>
      </list-item>
      <list-item>
       <p>TDF should be avoided in cases of nephrotoxicity</p>
      </list-item>
      <list-item>
       <p>In cases of H-monoresistant or poly-DR-TB: R to be substituted with rifabutin or rifapentine if patient is on PI or integrase inhibitor–based ART</p>
      </list-item>
      <list-item>
       <p>Dosage of integrase inhibitor to be doubled</p>
      </list-item>
      <list-item>
       <p>If a patient is on Bdq-based regimen, TDF, Azt, Nvp, or Dtg preferred over Efv or PI</p>
      </list-item>
      <list-item>
       <p>No interaction with Dlm-based regimen</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">
     <bold>Shorter regimens for M/XDR-TB</bold>
     <break/>
     <bold>WHO-approved</bold>
     <break/>
     <bold>STREAM 1 (regimen B)</bold>
     <list list-type="bullet">
      <list-item>
       <p>IP (4–6 months): Km/Am + high-dose H + Eto or Pto + Mfx or Gfx + Cfz + E + Z</p>
      </list-item>
     </list>
     <break/>CP (5 months): Mfx or Gfx + Cfz + E +Z
     <break/>
     <bold>Ongoing trials with proposed regimens (yet to be approved)</bold>
     <break/>
     <bold>MDR-TB</bold>
     <break/>
     <bold>STREAM 2 (regimen C)</bold>
     <list list-type="bullet">
      <list-item>
       <p>IP (4 months): high-dose H + Pto + Bdq + Lfx + Cfz + E + Z</p>
      </list-item>
     </list>
     <break/>CP (6 months): Bdq + Lfx + Cfz + E + Z
     <break/>
     <bold>STREAM 2 (Regimen D)</bold>
     <list list-type="bullet">
      <list-item>
       <p>IP – (2 months)- Km + High dose H + Bdq + Lfx + Cfz + Z</p>
      </list-item>
     </list>
     <break/>CP- (4–5 months)- Bdq + Lfx + Cfz + Z
     <break/>
     <bold>End TB</bold>
     <list list-type="bullet">
      <list-item>
       <p>
        <bold>Regimen A (9 months):</bold> Bdq + Lzd + Mfx + Z
       </p>
      </list-item>
      <list-item>
       <p>
        <bold>Regimen B (9 months):</bold> Bdq + Lzd + Cfz + Lfx + Z
       </p>
      </list-item>
      <list-item>
       <p>
        <bold>Regimen C (9 months):</bold> Bdq + Dlm + Lzd + Lfx + Z
       </p>
      </list-item>
      <list-item>
       <p>
        <bold>Regimen D (9 months):</bold> Dlm + Cfz + Lzd + Lfx + Z
       </p>
      </list-item>
      <list-item>
       <p>
        <bold>Regimen E (9 months):</bold> Dlm + Cfz + Mfx + Z
       </p>
      </list-item>
     </list>
    </td>
    <td rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">
     <bold>NeXT</bold>
     <list list-type="bullet">
      <list-item>
       <p>6–9 months: Bdq + Lzd + Lfx or Mfx + Eto or Pto/high-dose H + Z</p>
      </list-item>
     </list>
     <break/>
     <bold>MDR-END</bold>
     <list list-type="bullet">
      <list-item>
       <p>9–12 months: Dlm + Lzd + Lfx or Mfx + Z</p>
      </list-item>
     </list>
     <break/>
     <bold>STAND</bold>
     <list list-type="bullet">
      <list-item>
       <p>6 months: Mfx + Ptm + Z</p>
      </list-item>
      <list-item>
       <p>6 months: Bdq + Mfx + Ptm + Z</p>
      </list-item>
     </list>
     <break/>
     <bold>SimpliciTB</bold>
     <list list-type="bullet">
      <list-item>
       <p>6 months: Bdq + Ptm + Mfx + Z</p>
      </list-item>
     </list>
     <break/>
     <bold>NIX (XDR-TB)</bold>
     <list list-type="bullet">
      <list-item>
       <p>6–9 months: Bdq + Ptm + Lzd</p>
      </list-item>
     </list>
     <break/>
     <bold>TB PRACTECAL (M/XDR-TB)</bold>
     <list list-type="bullet">
      <list-item>
       <p>
        <bold>Regimen B (6 months):</bold> Bdq + Ptm + Lzd + Mfx
       </p>
      </list-item>
      <list-item>
       <p>
        <bold>Regimen C (6 months):</bold> Bdq + Ptm + Lzd + Cfz
       </p>
      </list-item>
      <list-item>
       <p>
        <bold>Regimen D (6 months):</bold> Bdq + Ptm + Lzd
       </p>
      </list-item>
     </list>
     <break/>
     <bold>BEAT (pre-XDR-TB and XDR-TB)</bold>
     <list list-type="bullet">
      <list-item>
       <p>6–9 months: Bdq + Dlm+ Lzd + Cfz</p>
      </list-item>
     </list>
    </td>
    <td rowspan="1" colspan="1"/>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>
    <bold>Note:</bold> Regimens can be modified further based on grouping of drugs recommended by WHO if there is documented resistance or intolerance to any of these drugs.
   </p>
  </fn>
 </table-wrap-foot>
</table-wrap>
